Welcome to our dedicated page for Crescent Biopharma news (Ticker: CBIO), a resource for investors and traders seeking the latest updates and insights on Crescent Biopharma stock.
Crescent Biopharma reports news about its clinical-stage oncology pipeline, including CR-001, a PD-1 x VEGF bispecific antibody, and antibody-drug conjugate programs such as CR-002 and CR-003. Company updates commonly cover clinical trial activity in solid tumors, pipeline combinations, collaboration activity, financial results, and business highlights.
Recurring corporate announcements also include investor conference presentations and equity inducement awards under the company’s employment inducement incentive plan. These updates reflect Crescent’s status as a Nasdaq-listed biotechnology issuer focused on cancer therapeutics.
Crescent Biopharma (Nasdaq: CBIO) announced that the independent Compensation Committee of its Board approved equity inducement awards for one non-executive employee under the 2025 Employment Inducement Incentive Award Plan. The grant consists of options to purchase an aggregate of 19,425 ordinary shares, approved on July 31, 2026, and intended to be material to the employee’s acceptance of employment in line with Nasdaq Listing Rule 5635(c)(4).
The stock options have a 10-year term and an exercise price of $14.47, equal to Crescent’s July 31, 2026 Nasdaq closing price. Vesting occurs as to one-fourth of the shares on the first anniversary of the employee’s start date, with the remaining shares vesting in equal monthly installments over the following three years, subject to continuous service and the terms of the Inducement Plan and the applicable option agreement.
Crescent Biopharma (Nasdaq: CBIO) reported second quarter 2026 results and clinical progress across its oncology pipeline. Cash and cash equivalents were $171.6 million as of June 30, 2026, with pro forma cash of $305.1 million after a July 2026 public offering that raised $143.7 million in gross proceeds, extending the expected cash runway into the second half of 2028.
Q2 2026 R&D expenses rose to $19.4 million from $12.1 million year over year, while G&A expenses were $8.7 million versus $8.9 million. Net loss for the quarter was $24.8 million, or $0.74 per basic and diluted share. Crescent highlighted ongoing enrollment in the global ASCEND Phase 1/2 trial of PD-1 x VEGF bispecific antibody CR-001, multiple China-based trials with partner Kelun-Biotech, and IND and trial initiation plans for ADC CR-002 in 2026 and CR-003 combination studies in 2027, with several proof-of-concept data readouts anticipated beginning in early 2027.
Crescent Biopharma (Nasdaq: CBIO) reported that the independent Compensation Committee of its Board approved equity inducement awards consisting of options to purchase an aggregate of 52,500 ordinary shares for two non-executive employees under the 2025 Employment Inducement Incentive Award Plan. The options were approved on July 22, 2026, have a 10-year term, and an exercise price of $15.83, equal to the closing price of Crescent’s shares on that date. According to Crescent Biopharma, each grant vests 25% on the first anniversary of the employee’s start date, with the remaining 75% vesting in equal monthly installments over the following three years, subject to continuous service and the terms of the Inducement Plan and individual option agreements.
Crescent Biopharma (Nasdaq: CBIO) closed its previously announced underwritten public offering, issuing 9,387,896 ordinary shares, including 1,293,103 shares from the underwriters’ fully exercised option, and pre-funded warrants to purchase up to 525,897 ordinary shares. Ordinary shares were priced at $14.50 and pre-funded warrants at $14.499 each, reflecting a $0.001 exercise price.
According to Crescent, the offering generated approximately $143.7 million in gross proceeds before underwriting discounts, commissions and expenses. All securities were sold by the company under an effective Form S-3 shelf registration. Jefferies, TD Cowen, Guggenheim Securities and Cantor served as joint book-running managers, with LifeSci Capital as passive book-runner.
Crescent Biopharma (Nasdaq: CBIO) priced an underwritten public offering of 8,094,793 ordinary shares and, in lieu of shares to certain investors, pre-funded warrants to purchase up to 525,897 ordinary shares. Ordinary shares are priced at $14.50 and pre-funded warrants at $14.499, with a $0.001 exercise price.
According to Crescent, expected gross proceeds are approximately $125 million before fees. Underwriters have a 30-day option to buy up to 1,293,103 additional shares. The offering is expected to close on July 16, 2026, subject to customary conditions, under an effective Form S-3 shelf registration.
Crescent Biopharma (Nasdaq: CBIO) commenced an underwritten public offering of ordinary shares and, for certain investors, pre-funded warrants to purchase ordinary shares. All securities in the proposed transaction will be offered by Crescent, and the company plans to grant underwriters a 30‑day option to buy up to an additional 15% of the ordinary shares at the public offering price, less underwriting discounts and commissions.
The offering is being made under an effective shelf registration statement on Form S‑3 declared effective on July 10, 2026 and remains subject to market and other conditions, with no assurance on timing, size, or completion. Jefferies, TD Cowen, Guggenheim Securities and Cantor are acting as joint book‑running managers, with LifeSci Capital as passive book‑running manager.
Crescent Biopharma (Nasdaq: CBIO) granted stock options as equity inducement awards to three non-executive employees under its 2025 Employment Inducement Incentive Award Plan. The awards cover 65,100 ordinary shares, have a 10-year term, and an exercise price of $16.99 per share, matching the June 25, 2026 Nasdaq closing price.
According to Crescent, the options were material to each employee’s acceptance of employment. Vesting occurs 25% on the first employment anniversary, then monthly over the remaining three years, subject to continuous service.
Crescent Biopharma (Nasdaq: CBIO) granted stock options as equity inducement awards to two non-executive employees under its 2025 Employment Inducement Incentive Award Plan.
The awards cover 23,550 shares total, have a 10-year term, a $17.57 exercise price, and time-based vesting tied to continued service.
Crescent Biopharma (Nasdaq: CBIO), a clinical-stage biotechnology company focused on cancer therapies, will present at two June 2026 investor conferences.
Management will host fireside chats at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs Global Healthcare Conference on June 8, with live webcasts and 90-day replays.
Crescent Biopharma (Nasdaq: CBIO) granted inducement stock options covering an aggregate 16,950 ordinary shares to two non-executive employees under its 2025 Employment Inducement Incentive Award Plan.
The options, approved May 28, 2026, have a 10-year term, a $21.47 exercise price, and time-based vesting over four years.